A phase IIa study to examining the efficacy of THX-110 [Dronabinol (synthetic Δ9-tetrahydracannabinol) and Palmitoylethanolamide (PEA)] for Chronic Low Back Pain.
Phase of Trial: Phase II
Latest Information Update: 31 May 2018
At a glance
- Drugs Dronabinol/palmitoylethanolamide (Primary)
- Indications Back pain
- Focus Adverse reactions; Therapeutic Use
- 31 May 2018 Status changed from planning to recruiting, according to a Therapix Biosciences media release.
- 31 May 2018 According to a Therapix Biosciences media release, this investigator-initiated trial has been started at the Clinical Research Institute, TN, USA.
- 23 Mar 2018 New trial record